RSV -

MMWR Booster for: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 / Weekly / March 7, 2024 / 73(9);209–214

Posted on March 8, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways High Effectiveness of Nirsevimab: Nirsevimab demonstrated a 90% effectiveness in preventing RSV-associated hospitalization among infants in their first RSV season. Median Time to Symptom Onset: The median